Key points are not available for this paper at this time.
Key Points BTKCys481 mutations, including multiple mutated variants within individual patients are common in ibrutinib-progressing WM patients. BTKCys481 mutations were associated with mutated CXCR4 in WM patients progressing on ibrutinib.
Xu et al. (Fri,) studied this question.